PROCEPT BioRobotics Corporation (PRCT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

PROCEPT BioRobotics Corpo... (PRCT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

81.58

-1.33 (-1.60%)

At close: Jan 14, 2025, 3:59 PM

undefined% (undefined)

Bid	66.6
Market Cap	4.44B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.95
PE Ratio (ttm)	-41.83
Forward PE	n/a
Analyst	Strong Buy

Ask	86.85
Volume	457,981
Avg. Volume (20D)	785,954
Open	84.27
Previous Close	82.91
Day's Range	79.65 - 84.68
52-Week Range	44.02 - 103.81
Beta	undefined

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Sep 15, 2021

Employees 626

Stock Exchange NASDAQ

Ticker Symbol PRCT

Website https://www.procept-biorobotics.com

Analyst Forecast

According to 7 analyst ratings, the average rating for PRCT stock is "Strong Buy." The 12-month stock price forecast is $102, which is an increase of 25.04% from the latest price.

Buy 71.43%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Next Earnings Release

PROCEPT BioRobotics Corporation is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $66.79M, reflecting a 53.25% YoY growth and earnings per share of -0.35, making a -35.19% decrease YoY.

Why Price Moved

2 months ago · Source

+32.33%

PROCEPT BioRobotics shares are trading higher afte... Unlock content with Pro Subscription

3 months ago · Source

+6.29%

PROCEPT BioRobotics shares are trading higher. Piper Sandler reiterated an Overweight rating and $75 price target.

News

1 month ago · https://thefly.com

Procept BioRobotics resumed with an Overweight at Wells Fargo

Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported...

1 month ago · seekingalpha.com

Procept BioRobotics: Continued Growth Runway Ahead

PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and op...

2 months ago · zacks.com

Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice

Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago · zacks.com

All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy

PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · benzinga.com

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential

PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.

2 months ago · seekingalpha.com

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Exec...

2 months ago · zacks.com

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.

2 months ago · zacks.com

Down -15.71% in 4 Weeks, Here's Why PROCEPT BioRobotics (PRCT) Looks Ripe for a Turnaround

PROCEPT BioRobotics (PRCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

2 months ago · zacks.com

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

PROCEPT BioRobotics (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.